President Trump is expected to unveil the measures Tuesday; Pfizer’s CEO expected to attend
By Natalie Andrews and Liz Essley WhyteUpdated Sept. 30, 2025 10:29 am ET
Pfizer headquarters in New York. Photo: angela weiss/AFP/Getty Images
WASHINGTON—The White House is planning to unveil a direct-to-consumer website for Americans to buy drugs, dubbed TrumpRx, while also announcing that Pfizer plans to lower prices on several of its medications in the U.S., according to people familiar with the matter.
TrumpRx would allow people to pay cash for certain drugs directly from a government website, at a discounted price negotiated by the government. It’s unclear how many drugs would be offered, or whether the website would be useful for the majority of Americans who are already covered by private insurance, Medicare or Medicaid.
Separately, Pfizer is expected to be the first to announce a plan to lower drug costs after President Trump pushed companies for months to lower prices in the U.S. More companies are expected to follow suit.
Trump and Albert Bourla, the chief executive of Pfizer, are set to announce the cost-cutting measure at the White House later today, according to a White House official. Bourla is also expected to announce a $70 billion investment in manufacturing medications in the U.S., according to Pfizer spokeswoman Amy Rose and a White House official.
The official estimated Pfizer’s lowered prices could benefit as many as 100 million patients.
“It’s a win for American patients, a win for American leadership, and it’s a win for Pfizer because it provides the certainty and stability we need to continue advancing new breakthrough medicines for patients,” said Rose.
“President Trump is leveraging the power of the federal government to drastically cut drug prices for everyday Americans,” said White House spokesman Kush Desai. “Democrats talked the talk for decades about drug prices, but only President Trump is actually walking the walk.”
Trump last week declared that branded drugs would face 100% tariffs if their manufacturers aren’t building facilities in the U.S. The new investments, along with others in the works that Bourla mentioned in an August earnings call, likely mean the company would be exempt from those tariffs.
Trump called for pharmaceutical companies to participate in a direct-to-consumer drug buying platform, and offer “most favored nation” pricing—commonly understood as prices lower or comparable to those in other developed nations—in a July letter.
Source (Archive)